Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

January 2017

Adlyxin (ad-LIKS-in) and Soliqua (soh-LEE-kwa) will be two new once-daily injectable meds for type 2 diabetes...and more are coming.

Adlyxin (lixisenatide) is the sixth "GLP-1 agonist" for diabetes...joining Bydureon, Byetta, Tanzeum, Trulicity, and Victoza.

Expect to see more than one Rx for patients starting on Adlyxin. Most patients will use the Starter Pack for one month...then switch to the Maintenance Pack long-term. Each pack will cost about $550.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

OTC Products Help Patients Prevent Overdoses and Mix-Ups With OTCs
Insurance Prioritize Urgent Prior Auth Requests to Avoid Gaps in Therapy
Diabetes Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds
End-of-Life Care Help With Unique End-of-Life Med Considerations
Obesity & Weight Loss Lomaira and Belviq XR Are New C-IV Meds for Weight Loss
Opioids Be Ready to Help More Patients Use Buprenorphine/Naloxone for Opioid Dependence
Calcium Send Patients With Questions About Calcium Supplements to the Pharmacist
Acne Help Patients Use New OTC Differin 0.1% Acne Gel Safely
Vaccines Expect Pregnant Women to Get Tdap Vaccine With Every Pregnancy
Dehydration Help Sort Through Options for Managing Dehydration in Kids
Inhalers Help Prevent Common Inhaler Errors

Adlyxin and Soliqua Join a Crowded Market of Injectable Diabetes Meds

Practical advice for a better career, with unlimited access to CE

Table of Contents